Signal2026-07-31
ClinicalTrials.gov

[PHASE3] Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

Part of

Innovative Obesity And Metabolic Therapies

Open primary sourceSee the whole picture